Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats

Cancer Research

Volumn 64, Issue 21, 2004, Pages 8045-8051

  Faivre, Jamila ^a,e   Clerc, Jérôme ^a   Gérolami, René ^b   Hervé, Julie ^a   Longuet, Michèle ^a   Liu, Bingkai ^a   Roux, Jérôme ^c   Moal, Frédéric ^c   Perricaudet, Michel ^d   Bréchot, Christian ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b TIMONE HOSPITAL   (France)

^c UNIVERSITÉ D'ANGERS   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COTRANSPORTER; RADIOACTIVE IODINE; RECOMBINANT DNA; SODIUM IODIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG RETENTION; DRUG TISSUE LEVEL; GENE CONSTRUCT; GENE TRANSFER; GENETIC RECOMBINATION; INJECTION; LIVER BLOOD FLOW; LIVER CANCER; LONG TERM CARE; MALE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; RAT;

ANIMALS; GENE THERAPY; IODINE RADIOISOTOPES; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; RATS; RATS, WISTAR; SYMPORTERS;

EID: 7444221297     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0893     Document Type: Article

References (41)

1. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458-60.
2. Smanik PA, Liu Q, Furminger TL, et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996;226:339-45.
3. Pinke LA, Dean DS, Bergert ER, Spitzweg C, Dutton CM, Morris JC. Cloning of the mouse sodium iodide symporter. Thyroid 2001;11:935-9.
4. Selmi-Ruby S, Watrin C, Trouttet-Masson S, et al. The porcine sodium/iodide symporter gene exhibits an uncommon expression pattern related to the use of alternative splice sites not present in the human or murine species. Endocrinology 2003;144:1074-85.
5. Tazebay UH, Wapnir IL, Levy O, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 2000;6:871-8.
6. Wapnir IL, van de Rijn M, Nowels K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 2003;88:1880-8.
7. Mandell RB, Mandell LZ, Link CJ, Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999;59:661-8.
8. De La Vieja A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000;80:1083-105.
9. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC. Clinical review 132: the sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001;86:3327-35.
10. Boland A, Ricard M, Opolon P, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000;60:3484-92.
11. Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003;63:7840-4.
12. Schipper ML, Weber A, Behe M, et al. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Res 2003;63:1333-8.
13. Nakamoto Y, Saga T, Misaki T, et al. Establishment and characterization of a breast cancer cell line expressing Na+/I- symporters for radioiodide concentrator gene therapy. J Nucl Med 2000;41:1898-904.
14. Sieger S, Jiang S, Schonsiegel F, et al. Tumour-specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3). Eur J Nucl Med Mol Imaging 2003;30:748-56.
15. Haberkorn U, Kinscherf R, Kissel M, et al. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther 2003;10:774-80.
16. Dadachova E, Carrasco N. The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med 2004;34:23-31.
17. Huang M, Batra RK, Kogai T, et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 2001;8:612-8.
18. Haberkorn U, Altmann A, Jiang S, Morr I, Mahmut M, Eisenhut M. Iodide uptake in human anaplastic thyroid carcinoma cells after transfer of the human thyroid peroxidase gene. Eur J Nucl Med 2001;28:633-8.
19. Boland A, Magnon C, Filetti S, et al. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid 2002;12:19-26.
20. Spitzweg C, Scholz IV, Bergert ER, et al. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells. Endocrinology 2003;144:3423-32.
21. Kogai T, Schultz JJ, Johnson LS, Huang M, Brent GA. Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci USA 2000;97:8519-24.
22. Schmutzler C. Regulation of the sodium/iodide symporter by retinoids - a review. Exp Clin Endocrinol Diabetes 2001;109:41-4.
23. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2003;103:1641-6.
24. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000;60:6526-30.
25. Groot-Wassink T, Aboagye EO, Glaser M, Lemoine NR, Vassaux G. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther 2002;13:1723-35.
26. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Reader AJ, Vassaux G. Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther 2004;9:436-42.
27. Rajewsky MF, Dauber W, Frankenberg H. Liver carcinogenesis by diethylnitrosamine in the rat. Science 1966;152:83-5.
28. Weiss SJ, Philp NJ, Grollman EF. Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology 1984;114:1090-8.
29. Zeng ZC, Tang ZY, Yang BH, et al. Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2002;29:1657-68.
30. Welcsh PL, Mankoff DA. Taking up iodide in breast tissue. Nature 2000;406:688-9.
31. Hooper PL, Turner JR, Conway MJ, Plymate SR. Thyroid uptake of 123I in a normal population. Arch Intern Med 1980;140:757-8.
32. Gerolami R, Cardoso J, Lewin M, et al. Evaluation of HSV-tk gene therapy in a rat model of chemically induced hepatocellular carcinoma by intratumoral and intrahepatic artery routes. Cancer Res 2000;60:993-1001.
33. Peto R, Gray R, Brantom P, Grasso P. Effects on 4080 rats of chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine: a detailed dose-response study. Cancer Res 1991;51:6415-51.
34. Smets LA, Janssen M, Metwally E, Loesberg C. Extragranular storage of the neuron blocking agent meta-iodobenzylguanidine (MIBG) in human neuroblastoma cells. Biochem Pharmacol 1990;39:1959-64.
35. Clerc J, Mardon K, Galons H, et al. Assessing intratumor distribution and uptake with MBBG versus MIBG imaging and targeting xenografted PC12-pheochromocytoma cell line. J Nucl Med 1995;36:859-66.
36. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
37. Sa Cunha A, Bonte E, Dubois S, et al. Inhibition of rat hepatocellular carcinoma tumor growth after multiple infusions of recombinant Ad.AFPtk followed by ganciclovir treatment. J Hepatol 2002;37:222-30.
38. Kramer MG, Barajas M, Razquin N, et al. In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther 2003;7:375-85.
39. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 2001;1:130-41.
40. Xue LY, Butler NJ, Makrigiorgos GM, Adelstein SJ, Kassis AI. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci USA 2002;99:13765-70.
41. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999;353:797-801.